SG11202001728YA - Enpp1 inhibitors and their use for the treatment of cancer - Google Patents
Enpp1 inhibitors and their use for the treatment of cancerInfo
- Publication number
- SG11202001728YA SG11202001728YA SG11202001728YA SG11202001728YA SG11202001728YA SG 11202001728Y A SG11202001728Y A SG 11202001728YA SG 11202001728Y A SG11202001728Y A SG 11202001728YA SG 11202001728Y A SG11202001728Y A SG 11202001728YA SG 11202001728Y A SG11202001728Y A SG 11202001728YA
- Authority
- SG
- Singapore
- Prior art keywords
- cancer
- treatment
- enpp1 inhibitors
- enpp1
- inhibitors
- Prior art date
Links
- 101150017770 ENPP1 gene Proteins 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/16—Esters of thiophosphoric acids or thiophosphorous acids
- C07F9/165—Esters of thiophosphoric acids
- C07F9/1651—Esters of thiophosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3826—Acyclic unsaturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/44—Amides thereof
- C07F9/4403—Amides thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4407—Amides of acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762556117P | 2017-09-08 | 2017-09-08 | |
| PCT/US2018/050018 WO2019051269A1 (en) | 2017-09-08 | 2018-09-07 | Enpp1 inhibitors and their use for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202001728YA true SG11202001728YA (en) | 2020-03-30 |
Family
ID=63714052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001728YA SG11202001728YA (en) | 2017-09-08 | 2018-09-07 | Enpp1 inhibitors and their use for the treatment of cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11701371B2 (en) |
| EP (2) | EP3678668B1 (en) |
| JP (2) | JP7292740B2 (en) |
| KR (1) | KR20200066292A (en) |
| CN (2) | CN117883449A (en) |
| AU (2) | AU2018330188C1 (en) |
| BR (1) | BR112020004559A2 (en) |
| CA (1) | CA3074268A1 (en) |
| DK (1) | DK3678668T3 (en) |
| EA (1) | EA202090595A1 (en) |
| IL (3) | IL302338B1 (en) |
| MA (1) | MA50082A (en) |
| MX (2) | MX2020002646A (en) |
| PL (1) | PL3678668T3 (en) |
| SG (1) | SG11202001728YA (en) |
| WO (1) | WO2019051269A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220056052A1 (en) * | 2018-12-28 | 2022-02-24 | Riboscience Llc | Quinazoline derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| WO2021053507A1 (en) | 2019-09-16 | 2021-03-25 | Aten Porus Lifesciences Pvt. Ltd. | 2-amino-s6-substituted thiopurine compounds as inhibitors of the enpp1 protein |
| EP4034094A4 (en) * | 2019-09-23 | 2024-01-24 | Nanjing Zhengxiang Pharmaceuticals Co Ltd | Phosphodiesterase inhibitors and use |
| TW202140439A (en) * | 2020-02-04 | 2021-11-01 | 美商史汀葛瑞醫療公司 | Inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (enpp1) and methods of use thereof |
| TWI794742B (en) | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | Antiviral compounds |
| CN115362150A (en) * | 2020-04-09 | 2022-11-18 | 贝达药业股份有限公司 | ENPP1 inhibitor, composition and application thereof |
| CN115996912A (en) * | 2020-05-04 | 2023-04-21 | 沃拉斯查疗法公司 | Iminothiolanone inhibitors of ENPP1 |
| CN115515939A (en) | 2020-05-08 | 2022-12-23 | 谛希诺生物科技有限公司 | Novel phthalazine derivatives having an inhibitory activity on ectonucleotide pyrophosphatase-phosphodiesterase and their use |
| KR20210136874A (en) | 2020-05-08 | 2021-11-17 | 주식회사 티씨노바이오사이언스 | Novel phthalazine derivatives as a Ectonucleotide pyrophosphatase-phosphodiesterase inhibitors and use thereof |
| WO2021257614A1 (en) * | 2020-06-16 | 2021-12-23 | Volastra Therapeutics, Inc. | Heterocyclic inhibitors of enpp1 |
| EP4208452A1 (en) | 2020-09-03 | 2023-07-12 | Immunesensor Therapeutics, Inc. | Quinoline cgas antagonist compounds |
| WO2022125613A1 (en) * | 2020-12-09 | 2022-06-16 | Stingray Therapeutics, Inc. | Phosphonates as inhibitors of enpp1 and cdnp |
| CA3200386A1 (en) | 2020-12-29 | 2022-07-07 | Seo Jung Han | Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof |
| KR20220095154A (en) | 2020-12-29 | 2022-07-06 | 주식회사 티씨노바이오사이언스 | Novel naphthyridinone derivatives as a Ectonucleotide pyrophosphatase-phosphodiesterase inhibitors and use thereof |
| MX2023008761A (en) | 2021-01-29 | 2023-08-22 | Txinno Bioscience Inc | Novel benzotriazole derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase, and use thereof. |
| KR20220110118A (en) | 2021-01-29 | 2022-08-05 | 주식회사 티씨노바이오사이언스 | Novel benzotriazole derivatives as a Ectonucleotide pyrophosphatase-phosphodiesterase inhibitors and use thereof |
| WO2022197734A1 (en) * | 2021-03-16 | 2022-09-22 | Riboscience Llc | Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors |
| US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
| CN115536696B (en) * | 2021-06-29 | 2023-07-14 | 上海齐鲁制药研究中心有限公司 | ENPP1 inhibitors |
| WO2023035001A1 (en) * | 2021-09-03 | 2023-03-09 | Angarus Therapeutics, Inc. | Enpp1 inhibitors and immune cells expressing chimeric antigen receptors |
| WO2023077083A1 (en) * | 2021-10-29 | 2023-05-04 | Angarus Therapeutics, Inc. | Enpp1 inhibitors as inhibitors of metastasis |
| WO2023197987A1 (en) * | 2022-04-11 | 2023-10-19 | 上海齐鲁制药研究中心有限公司 | Enpp1 inhibitor |
| WO2023212154A1 (en) | 2022-04-29 | 2023-11-02 | Petragen, Inc. | Inhibitors of enpp1 and modulation of bone growth |
| CN114767863B (en) * | 2022-04-29 | 2024-01-30 | 西北工业大学 | Application of ENPP2 gene or protein in regulation and control of colorectal cancer cells |
| WO2024028727A1 (en) * | 2022-08-01 | 2024-02-08 | Sravathi Ai Technology Private Limited | Novel ectonucleotide pyrophosphatase / phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA228044A (en) | 1923-01-16 | Thomas Noble Boughton | Die for forming bolts | |
| CA190896A (en) | 1919-02-24 | 1919-06-17 | Josephat C. Bergeron | Advertising device |
| DE3319795A1 (en) | 1983-06-01 | 1984-12-06 | Hoechst Ag, 6230 Frankfurt | METHOD FOR PRODUCING PHOSPHONIC ACID ESTERS |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| ES2150664T3 (en) | 1995-04-21 | 2000-12-01 | Teikoku Hormone Mfg Co Ltd | NEW PEPTIDE DERIVATIVES. |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| EP1490362A2 (en) * | 2001-03-08 | 2004-12-29 | Millennium Pharmaceuticals, Inc. | (homo)piperazine substituted quinolines for inhibiting the phosphorylation of kinases |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| ATE438644T1 (en) | 2002-12-24 | 2009-08-15 | Astrazeneca Ab | CHINAZOLINE DERIVATIVES |
| US20070004763A1 (en) | 2005-06-10 | 2007-01-04 | Nand Baindur | Aminoquinoline and aminoquinazoline kinase modulators |
| US10543207B2 (en) | 2008-12-31 | 2020-01-28 | Ardelyx, Inc. | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
| AR083199A1 (en) * | 2010-09-29 | 2013-02-06 | Intervet Internationale B V | N-HETEROARILO COMPOUNDS WITH CYCLE BRIDGE UNIT |
| EP2794630A4 (en) | 2011-12-22 | 2015-04-01 | Alios Biopharma Inc | Substituted phosphorothioate nucleotide analogs |
| JP2016518140A (en) | 2013-05-03 | 2016-06-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Method for inducing cyclic dinucleotide of type I interferon |
| MY175308A (en) | 2013-05-18 | 2020-06-18 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene"-dependent signalling |
| RU2704008C2 (en) * | 2014-09-22 | 2019-10-23 | Нэшнл Хелс Ресерч Инститьютс | Heterocyclic compounds and use thereof |
| US10011600B2 (en) * | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| CN105153153A (en) | 2015-08-31 | 2015-12-16 | 吉林奥来德光电材料股份有限公司 | Novel aromatic amine compound and preparation and application thereof |
| TWI659949B (en) | 2016-05-16 | 2019-05-21 | 臺北醫學大學 | Histone deacetylase 6 inhibitors and use thereof |
| MX2019007276A (en) | 2016-12-22 | 2019-11-11 | Mavupharma Inc | Compositions and methods of enhancing or augmenting type i ifn production. |
| WO2018127928A1 (en) | 2017-01-09 | 2018-07-12 | The Australian National University | Synergists for improved pesticides |
| US10518257B2 (en) | 2017-05-04 | 2019-12-31 | Exxonmobil Research And Engineering Company | Metal organic frameworks, their synthesis and use |
| WO2018229139A1 (en) | 2017-06-14 | 2018-12-20 | Fundación Para La Investigación Médica Aplicada | Novel compounds for use in cancer |
| WO2019046778A1 (en) * | 2017-08-31 | 2019-03-07 | Mavupharma, Inc. | Ectonucleotide pyrophosphatase-phosphodiesterase 1 (enpp-1) inhibitors and uses thereof |
| EP3917536A4 (en) | 2019-02-01 | 2022-11-23 | The Board of Trustees of the Leland Stanford Junior University | Enpp1 inhibitors and methods of modulating immune response |
| CN114437128B (en) * | 2022-01-28 | 2023-12-19 | 中国科学院长春应用化学研究所 | Choline phosphate modified taxol medicine and preparation method and application thereof |
-
2018
- 2018-09-07 PL PL18779884.8T patent/PL3678668T3/en unknown
- 2018-09-07 EP EP18779884.8A patent/EP3678668B1/en active Active
- 2018-09-07 CN CN202311760294.3A patent/CN117883449A/en active Pending
- 2018-09-07 WO PCT/US2018/050018 patent/WO2019051269A1/en active Application Filing
- 2018-09-07 CN CN201880063793.8A patent/CN111372587B/en active Active
- 2018-09-07 US US16/645,300 patent/US11701371B2/en active Active
- 2018-09-07 EP EP24150802.7A patent/EP4327882A3/en active Pending
- 2018-09-07 IL IL302338A patent/IL302338B1/en unknown
- 2018-09-07 KR KR1020207007008A patent/KR20200066292A/en not_active Application Discontinuation
- 2018-09-07 EA EA202090595A patent/EA202090595A1/en unknown
- 2018-09-07 AU AU2018330188A patent/AU2018330188C1/en active Active
- 2018-09-07 BR BR112020004559-4A patent/BR112020004559A2/en unknown
- 2018-09-07 CA CA3074268A patent/CA3074268A1/en active Pending
- 2018-09-07 IL IL311010A patent/IL311010A/en unknown
- 2018-09-07 IL IL272948A patent/IL272948B2/en unknown
- 2018-09-07 SG SG11202001728YA patent/SG11202001728YA/en unknown
- 2018-09-07 DK DK18779884.8T patent/DK3678668T3/en active
- 2018-09-07 JP JP2020513331A patent/JP7292740B2/en active Active
- 2018-09-07 MA MA050082A patent/MA50082A/en unknown
- 2018-09-07 MX MX2020002646A patent/MX2020002646A/en unknown
-
2020
- 2020-03-06 MX MX2023007193A patent/MX2023007193A/en unknown
-
2022
- 2022-09-30 US US17/957,392 patent/US11707471B2/en active Active
-
2023
- 2023-05-16 US US18/197,877 patent/US20230277570A1/en active Pending
- 2023-05-31 JP JP2023089900A patent/JP2023101715A/en active Pending
-
2024
- 2024-01-10 AU AU2024200148A patent/AU2024200148A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272948B1 (en) | Enpp1 inhibitors and their use for the treatment of cancer | |
| HK1249524A1 (en) | Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers | |
| ZA201607415B (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
| HK1247630A1 (en) | Compositions and methods for enhancing the efficacy of cancer therapy | |
| IL267795A (en) | Combination therapy for the treatment of cancer | |
| ZA201900960B (en) | Methods and compositions for the treatment of cancer | |
| HRP20190888T8 (en) | Igf-1r antibody-drug-conjugate and its use for the treatment of cancer | |
| HK1259545A1 (en) | Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer | |
| IL247586A0 (en) | Use of eribulin and mtor inhibitors as combination therapy for the treatment of cancer | |
| IL266486A (en) | Pharmaceutical compositions and methods for the treatment of cancer | |
| IL274198A (en) | Use of nox inhibitors for treatment of cancer | |
| EP3370773A4 (en) | Combination therapy of immunotoxin and checkpoint inhibitor | |
| IL280587B (en) | Flurocytidine derivatives and its composition for the treatment of cancer | |
| IL264451B1 (en) | Combination of abt-199 and imetelstat for treatment of aml | |
| IL266993A (en) | Combination therapy for the treatment of cancer | |
| ZA201900984B (en) | Methods and compositions for the treatment of warts | |
| IL272147A (en) | Methods and compositions for the treatment of cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| EP3615052A4 (en) | Use of hcn inhibitors for treatment of cancer | |
| IL253642A0 (en) | Combination therapy for the treatment of cancer |